Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid

Palkovits, S; Seidel, G; Pertl, L; Malle, EM; Hausberger, S; Makk, J; Singer, C; Osterholt, J; Herzog, SA; Haas, A; Weger, M.
MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Retina. 2017; 37(12):2262-2268
Web of Science PubMed FullText FullText_MUG

 

Authors Med Uni Graz:
Haas Anton
Hausberger Silke
Herzog Sereina Annik
Makk Johanna
Malle Eva Maria
Palkovits Stefan
Posch-Pertl Laura
Seidel Gerald
Singer Christoph
Weger Martin
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To evaluate the effect of intravitreal bevacizumab on the macular choroidal volume and the subfoveal choroidal thickness in treatment naïve eyes with exudative age-related macular degeneration. The macular choroidal volume and the subfoveal choroidal thickness were measured using enhanced depth imaging optical coherence tomography. After a screening examination, each patient received 3 monthly intravitreal injections of 1.25 mg bevacizumab. One month after the third injection was a final assessment. Forty-seven patients with a mean age of 80 ± 6.4 years were included. The macular choroidal volume decreased significantly from median 4.1 mm (interquartile range 3.4-5.9) to median 3.9 mm (interquartile range 3.1-5.6) between the baseline and final examination (difference -0.46 mm, 95% confidence interval: -0.57 to 0.35, P < 0.001). Similarly, subfoveal choroidal thickness had decreased from 157.0 μm (interquartile range 116.0-244.5) at baseline to 139.0 μm (interquartile range 102.5-212.0) at the final examination (P < 0.001). Both parameters macular choroidal volume at baseline and subfoveal choroidal thickness at baseline were not associated with the response to treatment. The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged, 80 and over -
Angiogenesis Inhibitors - administration & dosage
Bevacizumab - administration & dosage
Choroid - pathology
Dose-Response Relationship, Drug -
Drug Administration Schedule -
Fluorescein Angiography - methods
Follow-Up Studies -
Fundus Oculi -
Humans -
Intravitreal Injections -
Macula Lutea - pathology
Middle Aged -
Organ Size -
Prospective Studies -
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Time Factors -
Tomography, Optical Coherence - methods
Treatment Outcome -
Visual Acuity -
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - drug therapy

Find related publications in this database (Keywords)
age-related macular degeneration
bevacizumab
choroidal thickness
choroidal volume
© Meduni GrazImprint